A Phase 1 Study of ES414 in Patients Wtih Metastatic Castration-Resistant Prostate Cancer

Trial Profile

A Phase 1 Study of ES414 in Patients Wtih Metastatic Castration-Resistant Prostate Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Jul 2018

At a glance

  • Drugs APVO-414 (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Sponsors Aptevo Therapeutics; Emergent Product Development Seattle
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 13 Mar 2018 According to an Aptevo Therapeutics media release, the company anticipates to complete enrollment of Phase 1 dosing cohorts in Q3 2018 and report preliminary data in Q4 2018.
    • 09 Jan 2018 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top